Overexpression of orphan G-Protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with β-catenin mutations

被引:179
作者
Yamamoto, Y
Sakamoto, M
Fujii, G
Tsuiji, H
Kanetaka, K
Asaka, M
Hirohashi, S
机构
[1] Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan
[2] Hokkaido Univ, Fac Med, Dept Internal Med 3, Sapporo, Hokkaido, Japan
关键词
D O I
10.1053/jhep.2003.50029
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To identify the genes responsible for carcinogenesis and progression of hepatocellular carcinoma (HCC), we screened differentially expressed genes in several human HCC cell lines. Among these genes, Gpr49 was up-regulated in PLC/PRF/5 and HepG2. Gpr49 is a member of the glycoprotein hormone receptor subfamily, which includes the thyroid-stimulating hormone receptor (TSHR). However, Gpr49 remains to be an orphan G-protein-coupled receptor. By real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) analysis, overexpression (>3-fold increase compared with the corresponding noncancerous liver tissue) of Gpr49 mRNA was observed in 18 of 38 (47%) HCCs compared with corresponding noncancerous livers. Clinicopathologically, overexpression of Gpr49 was frequently observed in HCC with mutation in beta-catenin exon 3 (14 of 16 cases, 87.5%). Moreover, introduction of mutant beta-catenin into mouse hepatocytes in culture caused up-regulation of the Gpr49 mouse homologue. Therefore, Gpr49 is likely to be a target gene activated by Wnt-signaling in HCC. In conclusion, although much is still unknown, Gpr49 may be critically involved in the development of HCCs with beta-catenin mutations and has the potential to be a new therapeutic target in the treatment of HCC.
引用
收藏
页码:528 / 533
页数:6
相关论文
共 26 条
[21]   Nuclear accumulation of mutated β-catenin in hepatocellular carcinoma is associated with increased cell proliferation [J].
Van Nhieu, JT ;
Renard, CA ;
Wei, Y ;
Cherqui, D ;
Zafrani, ES ;
Buendia, MA .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (03) :703-710
[22]  
Xu LF, 2000, GENE DEV, V14, P585
[23]  
Yamada T, 2000, CANCER RES, V60, P4761
[24]  
Yamamoto Y, 2001, CLIN CANCER RES, V7, P297
[25]  
YANO H, 1986, IN VITRO CELL DEV B, V22, P637
[26]  
YANO H, 1988, ACTA PATHOL JAPON, V38, P953